Reprogramming t cells and hematopoietic cells

Abstract

Methods and compositions relating to the production of induced pluripotent stem cells (iPS cells) are disclosed. For example, induced pluripotent stem cells may be generated from CD34 + hematopoietic cells, such as human CD34 + blood progenitor cells, or T cells. Various iPS cell lines are also provided. In certain embodiments, the invention provides novel induced pluripotent stem cells with a genome comprising genetic rearrangement of T cell receptors.

1 . A method for producing induced pluripotent stem cells from T cells or CD34 +  hematopoietic progenitor cells comprising the steps of:
 (a) obtaining a cell population comprising T cells or CD34 +  hematopoietic progenitor cells, wherein the CD34 +  hematopoietic progenitor cells are from a subject whose cells have not been mobilized with extrinsically applied granulocyte colony-stimulating factor (G-CSF); and 
 (b) producing iPS cells from the T cells or CD34 +  hematopoietic progenitor cells of the cell population through the introduction of nucleic acids encoding reprogramming factors comprised in one or more viral vectors, and culturing the cells under defined, feeder-free conditions to provide an iPS cell population. 
 
     
     
         2 . The method of  claim 1 , wherein the source of the cell population is a blood sample, blood components, bone marrow, lymph node, fetal liver, or umbilical cord. 
     
     
         3 . The method of  claim 2 , wherein the source of the cell population is a blood sample of from about 1 to about 5 ml. 
     
     
         4 . The method of  claim 3 , wherein the source of the cell population is a blood sample of about 3 ml. 
     
     
         5 . The method of  claim 1 , wherein the source of the cell population comprising T cells is a subject whose cells have not been mobilized with extrinsically applied G-CSF. 
     
     
         6 . The method of  claim 1 , wherein the cell population has been cryopreserved. 
     
     
         7 . The method of  claim 1 , wherein the cell population comprising T cells is prepared in vitro or in vivo under conditions that will activate the T cells. 
     
     
         8 . The method of  claim 7 , wherein a cell population comprising T cells is cultured in the presence of an anti-CD3 antibody. 
     
     
         9 . The method of  claim 1 , wherein the cell population comprising T cells or CD34 +  hematopoietic progenitor cells is cultured in vitro with one or more cytokines to expand the T cell or CD34 +  hematopoietic progenitor cells population therein. 
     
     
         10 . The method of  claim 9 , wherein the cell population comprises T cells, and wherein the one or more cytokines comprises IL-2. 
     
     
         11 . The method of  claim 9 , wherein the cell population comprises CD34 +  hematopoietic progenitor cells, and wherein the one or more cytokines comprises at least one of SCF, Flt3L, or IL-3. 
     
     
         12 . The method of  claim 1 , wherein the T cells are human T cells. 
     
     
         13 . The method of  claim 1 , wherein the CD34 +  hematopoietic progenitor cells are human CD34 +  hematopoietic progenitor cells. 
     
     
         14 . The method of  claim 1 , wherein the T cells are CD4 +  or CD8 +  T cells. 
     
     
         15 . The method of  claim 1 , wherein the T cells are T helper 1 (TH1) cells, T helper 2 (TH2) cells, TH17 cells, cytotoxic T cells, regulatory T cells, natural killer T cells, naïve T cells, memory T cells, or gamma delta T cells. 
     
     
         16 . The method of  claim 1 , wherein the cell population comprises from about 90% to about 99% T cells. 
     
     
         17 . The method of  claim 1 , wherein the cell population comprises from about 97% to about 99% T cells. 
     
     
         18 . The method of  claim 1 , wherein the cell population comprises at least 1×10 3  T cells. 
     
     
         19 . The method of  claim 1 , wherein the cell population comprises at least 5×10 3  T cells. 
     
     
         20 . The method of  claim 1 , wherein the cell population comprises from about 1×10 6  to about 2×10 6  T cells. 
     
     
         21 .- 23 . (canceled) 
     
     
         24 . The method of  claim 1 , wherein the reprogramming factors are encoded by one or more expression cassettes and comprise a Sox family protein and an Oct family protein. 
     
     
         25 . The method of  claim 24 , wherein the one or more expression cassettes comprise at least a polycistronic transcript unit. 
     
     
         26 . The method of  claim 25 , wherein the polycistronic transcript unit comprises at least two reprogramming genes. 
     
     
         27 . The method of  claim 26 , wherein the polycistronic transcript unit comprises a Sox gene and an Oct gene. 
     
     
         28 . The method of  claim 26 , wherein the polycistronic transcript unit comprises a cMyc gene and a Klf4 gene. 
     
     
         29 . The method of  claim 26 , wherein the polycistronic transcript unit comprises a Nanog gene and an Lin28 gene. 
     
     
         30 . The method of  claim 25 , wherein the polycistronic transcript unit comprises a reprogramming gene and a selectable or screenable marker. 
     
     
         31 . The method of  claim 25 , wherein the polycistronic transcription unit comprises an internal ribosome entry site (IRES) or a sequence coding for at least one protease cleavage site and/or self-cleaving peptide for polycistronic transcription. 
     
     
         32 . (canceled) 
     
     
         33 . The method of  claim 1 , wherein the reprogramming vector is a retroviral vector. 
     
     
         34 . The method of  claim 24 , wherein the Sox family protein is Sox2. 
     
     
         35 . The method of  claim 24 , wherein the Oct family protein is Oct4. 
     
     
         36 . The method of  claim 24 , wherein the reprogramming proteins further comprise Nanog, Lin28, c-Myc, Klf4, or Esrrb. 
     
     
         37 . The method of  claim 36 , wherein the reprogramming proteins further comprise Nanog. 
     
     
         38 . The method of  claim 36 , wherein the reprogramming proteins further comprise Klf4 and c-Myc. 
     
     
         39 . The method of  claim 1 , wherein producing iPS cells from the T cells or CD34 +  hematopoietic progenitor cells of the population further comprises selecting the iPS cells for one or more characteristics of embryonic stem cells. 
     
     
         40 . The method of  claim 39 , wherein the characteristic is an adherent property, an undifferentiated morphology, an embryonic stem cell-specific marker or pluripotency. 
     
     
         41 . The method of  claim 40 , wherein the characteristic is an adherent property. 
     
     
         42 . The method of  claim 40 , wherein the characteristic is an undifferentiated morphology. 
     
     
         43 . The method of  claim 1 , wherein the method further comprises differentiating the iPS cells to a differentiated cell. 
     
     
         44 . The method of  claim 43 , wherein the differentiated cell comprises a cardiomyocyte, a hematopoietic cell, a neuron, a fibroblast or an epidermal cell. 
     
     
         45 . The method of  claim 1 , wherein the iPS cell population is essentially free of integrated, exogenous viral elements. 
     
     
         46 .- 49 . (canceled)